This symposium will review state-of the art practice in acute stroke management, with emphasis on the new expanded window of treatment. Health professionals with a stroke focus will gain a better understanding of the new 2018 American Heart Association guidelines for acute ischemic stroke, the new science in atrial cardiomyopathies and post stroke management. Global health impact of stroke will also be featured, as well as, an update on translational stroke research.
This year’s theme is “Windows of Hope” and will focus on:
Expanded window of thrombectomy rescue for some stroke patients
Update on clinical practice guidelines in stroke care from recent landmark studies
Guidance in palliative care in stroke
Nursing topic break-out sessions
Targeting gaps in transition of care
This activity is intended for providers in the specialties of Neurological Surgery, Neurology, Emergency Medicine and Internal Medicine. Physicians, Physician Assistants, Nurse Practitioners, Registered Nurses, Pharmacists and therapists who are interested in advancing their knowledge in stroke care are encouraged to attend.
Upon completion of this activity, participants should be able to:
Explain new evidence of expanding acute stroke thrombectomy treatment in elected patients to 24 hr last known well and to review all the new guidelines that focused on strict evidence in recommendations, and thus lowered evidence in areas that were lacking (such chemical prophylaxis in VTE prophylaxis and routine ordering of MRI).
Apply appropriate selection of medical management of hyperlipidemia in stroke care including new PSK Inhibitors.
Distinguish the difference in known atrial fibrillation and the contribution to stroke risk of atrial cardiopathies overall.
Summarize the indication for PFO closure in selected patients post stroke.
Identify the global impact of stroke and how healthcare workers everywhere share the burden of care and prevention.
Recognize the impact of meaningful and targeted therapies, including new evidence in rehabilitation stroke medicine.
Explain the current state of this targeted science, including trials that are ongoing now.